Increased expression levels of Syntaxin 1A and Synaptobrevin 2/Vesicle-Associated Membrane Protein-2 are associated with the progression of bladder cancer

Raja, Sadaf Azad; Abbas, Seher; Shah, S. P.; Tariq, Aamira; Bibi, Nazia; Yousuf, Arzu; Khawaja, Athar; Nawaz, Muhammad Asif; Mehmood, Arshad; Khan, Muhammad Jadoon; Hussain, Alamdar

doi:10.1590/1678-4685-gmb-2017-0339

Cited by 11 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…several types of cancers including prostate cancer, bladder cancer and papillary renal cell carcinoma (Peak et al 2019(Peak et al , 2020Raja et al 2019). STXBP1 is previously reported to regulate the assemble of SNARE, which is the main machinery for secretion.…”

Section: Discussionmentioning

confidence: 99%

Membrane Location of Syntaxin-Binding Protein 1 Is Correlated with Poor Prognosis of Lung Adenocarcinoma

Wang

Wen

et al. 2020

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related death, and adenocarcinoma is the most common histological type of lung cancer. Syntaxin-binding protein 1 (STXBP1) is essential for exocytosis of secretory vesicles. Since exocytosis is the basic cellular process of cells, we investigated STXBP1 expression and clinical significance in lung adenocarcinoma. We performed quantitative real-time polymerase chain reaction in 20 pairs of lung adenocarcinoma and paired normal tissues, and demonstrated that the relative expression levels of STXBP1 mRNA in lung adenocarcinoma was significantly higher than those in normal lung tissues. We then carried out immunohistochemistry (IHC) to determine the expression profile of STXBP1 in 276 lung adenocarcinoma specimens, and categorized patients into subgroups with low or high STXBP1 expression, based on the IHC score. Moreover, STXBP1 expression phenotypes were categorized as membrane, cytoplasm, and mixed expression (both membrane and cytoplasm) expression. High STXBP1 protein accounted for 58.0% of all the 276 cases (160/276), and membrane, cytoplasm or mixed STXBP1 accounted for 28.75%, 25.63% and 45.63% in the 160 cases of high STXBP1 expression. The clinical significances of these phenotypes were evaluated by analyzing their correlation with clinicopathological factors, as well as their prognostic values. Consequently, the whole STXBP1 expression or membranal STXBP1 expression were correlated with poor prognosis and were independent prognostic factors of lung adenocarcinoma. The whole and membranal STXBP1 expression are independent prognostic factors of lung adenocarcinoma. STXBP1 detection is capable to help screen patients who may have poor prognosis and strengthen the adjuvant therapy more precisely.

show abstract

Section: Discussionmentioning

confidence: 99%

Membrane Location of Syntaxin-Binding Protein 1 Is Correlated with Poor Prognosis of Lung Adenocarcinoma

Wang

Wen

et al. 2020

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Of note, VAMP3 has been reported to be involved in CXCL6 and TNF-a release from the synovial sarcoma cell line SW982, indicating an active role of VAMP proteins in diffusible mediator secretion from cancer cells (80). Furthermore, studies have reported enhanced expression of V-SNARE and t-SNARE members in cancer cells along the course of tumor progression, which may further promote the exocytic release of the mediators in the TME (81).…”

Section: Exocytic Trafficking Pathwaysmentioning

confidence: 99%

The Recruitment of Neutrophils to the Tumor Microenvironment Is Regulated by Multiple Mediators

2021

View full text Add to dashboard Cite

Neutrophils sense and migrate towards chemotactic factors released at sites of infection/inflammation and contain the affected area using a variety of effector mechanisms. Aside from these established immune defense functions, neutrophils are emerging as one of the key tumor-infiltrating immune cells that influence cancer progression and metastasis. Neutrophil recruitment to the tumor microenvironment (TME) is mediated by multiple mediators including cytokines, chemokines, lipids, and growth factors that are secreted from cancer cells and cancer-associated stromal cells. However, the molecular mechanisms that underlie the expression and secretion of the different mediators from cancer cells and how neutrophils integrate these signals to reach and invade tumors remain unclear. Here, we discuss the possible role of the epithelial to mesenchymal transition (EMT) program, which is a well-established promoter of malignant potential in cancer, in regulating the expression and secretion of these key mediators. We also summarize and review our current understanding of the machineries that potentially control the secretion of the mediators from cancer cells, including the exocytic trafficking pathways, secretory autophagy, and extracellular vesicle-mediated secretion. We further reflect on possible mechanisms by which different mediators collaborate by integrating their signaling network, and particularly focus on TGF-β, a cytokine that is highly expressed in invasive tumors, and CXCR2 ligands, which are crucial neutrophil recruiting chemokines. Finally, we highlight gaps in the field and the need to expand current knowledge of the secretory machineries and cross-talks among mediators to develop novel neutrophil targeting strategies as effective therapeutic options in the treatment of cancer.

show abstract

“…In order to detect the functions and applications of these closest neighbors of the CHGA, literature verifications were performed. We searched relevant published papers from PubMed and Google scholar concerning these nearby proteins and cancers, and found that SCG3 was convinced as a prognostic biomarker for lung cancer [35] and rectal cancer [36]; SST expression was reported to have a strong relationship with advanced CRC [37]; NCAM1 was correlated with several human cancers [38]; ENO2 were predicted as treatment biomarker for acute lymphoblastic leukemia [39]; SYT1 expression was a candidate colon cancer biomarker [40]; STAX1 was proved to be associated with the transformation of high-grade tumors in the bladder cancer [41]; and as a paralog for CHGA, CHGB was a prognostic marker for the pancreatic neuroendocrine tumors [21]. Expression of SLC22A8 was considered as a valuable biomarker for the lung cancer treatment [42].…”

Section: Discussionmentioning

confidence: 99%

Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients

Zhang

Shen

Sun

2019

IJMS

View full text Add to dashboard Cite

Colon cancer is one of the major causes of cancer death worldwide. The five-year survival rate for the early-stage patients is more than 90%, and only around 10% for the later stages. Moreover, half of the colon cancer patients have been clinically diagnosed at the later stages. It is; therefore, of importance to enhance the ability for the early diagnosis of colon cancer. Taking advantages from our previous studies, there are several potential biomarkers which have been associated with the early diagnosis of the colon cancer. In order to investigate these early diagnostic biomarkers for colon cancer, human chromogranin-A (CHGA) was further analyzed among the most powerful diagnostic biomarkers. In this study, we used a logistic regression-based meta-analysis to clarify associations of CHGA expression with colon cancer diagnosis. Both healthy populations and the normal mucosa from the colon cancer patients were selected as the double normal controls. The results showed decreased expression of CHGA in the early stages of colon cancer as compared to the normal controls. The decline of CHGA expression in the early stages of colon cancer is probably a new diagnostic biomarker for colon cancer diagnosis with high predicting possibility and verification performance. We have also compared the diagnostic powers of CHGA expression with the typical oncogene KRAS, classic tumor suppressor TP53, and well-known cellular proliferation index MKI67, and the CHGA showed stronger ability to predict early diagnosis for colon cancer than these other cancer biomarkers. In the protein–protein interaction (PPI) network, CHGA was revealed to share some common pathways with KRAS and TP53. CHGA might be considered as a novel, promising, and powerful biomarker for early diagnosis of colon cancer.

show abstract

Increased expression levels of Syntaxin 1A and Synaptobrevin 2/Vesicle-Associated Membrane Protein-2 are associated with the progression of bladder cancer

Cited by 11 publications

References 34 publications

Membrane Location of Syntaxin-Binding Protein 1 Is Correlated with Poor Prognosis of Lung Adenocarcinoma

Membrane Location of Syntaxin-Binding Protein 1 Is Correlated with Poor Prognosis of Lung Adenocarcinoma

The Recruitment of Neutrophils to the Tumor Microenvironment Is Regulated by Multiple Mediators

Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients

Contact Info

Product

Resources

About